Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001628280-18-007584
Filing Date
2018-06-05
Accepted
2018-06-05 08:59:58
Documents
63
Period of Report
2018-04-30

Document Format Files

Seq Description Document Type Size
1 6-K Q1 APRIL 2018 a6-kq1april2018xfrontpage.htm 6-K 26411
2 EXHIBIT 99.1 rns-q1april2018.htm EX-99.1 491149
3 EXHIBIT 99.2 ias34-q1april2018.htm EX-99.2 511993
10 summitlogo.jpg GRAPHIC 5395
  Complete submission text file 0001628280-18-007584.txt   3946348

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT smmt-20180430.xml EX-101.INS 676189
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20180430.xsd EX-101.SCH 47609
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT smmt-20180430_cal.xml EX-101.CAL 58580
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20180430_def.xml EX-101.DEF 119255
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20180430_lab.xml EX-101.LAB 420944
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20180430_pre.xml EX-101.PRE 241077
Mailing Address 136A EASTERN AVENUE MILTON PARK ABINGDON X0 OX14 4SB
Business Address 136A EASTERN AVENUE MILTON PARK ABINGDON X0 OX14 4SB 44-123-544-3939
Summit Therapeutics plc (Filer) CIK: 0001599298 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 0114
Type: 6-K | Act: 34 | File No.: 001-36866 | Film No.: 18880197
SIC: 2834 Pharmaceutical Preparations